STOCKHOLM - October 29, 2025 - Inify Laboratories, a unique laboratory service
that provides cancer diagnostics within pathology, expanded its service offering
during the third quarter with the addition of a second diagnostic area:
gastroenterology. In September, the company launched gastrointestinal
diagnostics services in Sweden, successfully diagnosing its first patient
samples.

"This marks the starting point for addressing a market with very large sample
volumes and enormous capacity needs. In Sweden alone, hundreds of thousands of
endoscopy examinations are performed annually, many of which result in tissue
sampling," says CEO Fredrik Palm of Inify Laboratories.

Sales growth in the third quarter was strong, with an increase of 76% compared
to the corresponding period last year, and 78% for the period January -
September. The subsidiary Inify Laboratories Nordics continues to support
expansion with its steady positive cashflow. Cash balance at the end of the
period amounted to SEK 112 million.

The sales growth from gastrointestinal diagnostics is expected to build
gradually from 2026 onwards.

Construction of Inify's laboratory in Milton Park, just south of Oxford in the
UK, is progressing according to plan. The goal of launching clinical operations
in early 2026 remains unchanged. Dialogues with customers - primarily the NHS -
also continue to progress steadily.

"We remain optimistic that agreements will be signed, enabling sales to commence
through our UK subsidiary in close connection with the opening of the new
laboratory," says Palm.

Inify's initial UK offering will focus on prostate cancer diagnostics, where
most customer dialogues are already well advanced. Following the launch of
gastrointestinal diagnostics in Sweden, the company will gradually introduce
this area into the UK operations.

"Continued growth, expansion into a new diagnostic area, progress in our UK
establishment, and clear examples of the potential in our standardised and
structured data - all of this, in my view, bodes well for a bright and exciting
future, with Inify taking on an increasingly prominent role in current and
future healthcare," says Palm.

For further information, please contact CEO Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com

###

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)